Julia Hinzmann
Overview
Explore the profile of Julia Hinzmann including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
17
Citations
1337
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ogbaini-Emovon E, Akpede G, Okogbenin S, Osagiede E, Tobin E, Asogun D, et al.
Open Forum Infect Dis
. 2024 Oct;
11(10):ofae575.
PMID: 39450398
Background: The standard of care for Lassa fever is the use of ribavirin with supportive therapy. There is little information on the course of viremia and its relationship with clinical...
2.
Gehre F, Lagu H, Achol E, Omari N, Ochido G, Duraffour S, et al.
BMJ Glob Health
. 2022 Dec;
7(12).
PMID: 36524412
No abstract available.
3.
Brinkmann N, Hoffmann C, Wurr S, Pallasch E, Hinzmann J, Ostermann E, et al.
Viruses
. 2022 Sep;
14(9).
PMID: 36146793
is the natural host of various arenaviruses, including the human-pathogenic Lassa virus. Homologous arenaviruses, defined here as those having as a natural host, can establish long-lasting infection in while these...
4.
Groger M, Akhideno P, Kleist C, Babatunde F, Edeawe O, Hinzmann J, et al.
Clin Infect Dis
. 2022 Jul;
76(3):e841-e848.
PMID: 35881530
Background: Lassa fever is endemic in large parts of West Africa. The recommended antiviral treatment is ribavirin. Two treatment regimens are currently endorsed in Nigeria: the "McCormick regimen" based on...
5.
Koundouno F, Kafetzopoulou L, Faye M, Renevey A, Soropogui B, Ifono K, et al.
N Engl J Med
. 2022 Jun;
386(26):2528-2530.
PMID: 35767445
No abstract available.
6.
Thielebein A, Ighodalo Y, Taju A, Olokor T, Omiunu R, Esumeh R, et al.
Lancet Microbe
. 2022 May;
3(1):e32-e40.
PMID: 35544114
Background: There is anecdotal evidence for Lassa virus persistence in body fluids. We aimed to investigate various body fluids after recovery from acute Lassa fever, describe the dynamics of Lassa...
7.
Keita A, Koundouno F, Faye M, Dux A, Hinzmann J, Diallo H, et al.
Nature
. 2021 Sep;
597(7877):539-543.
PMID: 34526718
Seven years after the declaration of the first epidemic of Ebola virus disease in Guinea, the country faced a new outbreak-between 14 February and 19 June 2021-near the epicentre of...
8.
Affara M, Lagu H, Achol E, Karamagi R, Omari N, Ochido G, et al.
BMC Med
. 2021 Jul;
19(1):160.
PMID: 34238298
Background: East Africa is home to 170 million people and prone to frequent outbreaks of viral haemorrhagic fevers and various bacterial diseases. A major challenge is that epidemics mostly happen...
9.
Olschewski S, Thielebein A, Hoffmann C, Blake O, Muller J, Bockholt S, et al.
Viruses
. 2021 Jun;
13(6).
PMID: 34073735
Several of the human-pathogenic arenaviruses cause hemorrhagic fever and have to be handled under biosafety level 4 conditions, including Lassa virus. Rapid and safe inactivation of specimens containing these viruses...
10.
Magassouba N, Koivogui E, Conde S, Kone M, Koropogui M, Soropogui B, et al.
Viruses
. 2020 Sep;
12(10).
PMID: 32977629
Lassa fever is a rodent-borne disease caused by Lassa virus (LASV). It causes fever, dizziness, vertigo, fatigue, coughing, diarrhea, internal bleeding and facial edema. The disease has been known in...